Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Familial Hypercholesterolemia, Adherence, Medication
Interventions: Monetary incentives; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lipid Metabolism Disorders, Hypertriglyceridemia
Interventions: EPA, DHA; Drug
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 9
States / cities: Culver City, California • Glendale, California • Miami, Florida + 4 more

Conditions: Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
Interventions: Coaching, Educational Outreach, Site Visits; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: Not listed
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more

Conditions: Coronary Heart Disease
Interventions: MPSK3169A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 34
States / cities: Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more

Conditions: Hypertriglyceridemia
Interventions: implitapide; Drug
Lead sponsor: Medical Research Laboratories International; Industry
Eligibility: 8 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Cincinnati, Ohio • Houston, Texas

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
Interventions: Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant; Genetic
Lead sponsor: Geisinger Clinic; Other
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases
Interventions: Comparison of dietary protein amino acid profile; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Adult Onset
Interventions: Cinnamon or placebo 500 mg capsule twice daily; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: HIV Infections, Hyperlipidemia
Interventions: oyster mushroom; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: Hypertension, Hyperlipidemia
Interventions: Free Generic Samples (hydrochlorothiazide, simvastatin); Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercholesterolemia, Familial
Interventions: ISIS 301012 or Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Chicago, Illinois • Auburn, Maine • Scarborough, Maine + 4 more

Conditions: Hypercholesteremia
Interventions: Gemcabene; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Hyperlipidemia
Interventions: Standard Process 21 Day Purification Program (SPPP); Other
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Hypertriglyceridemia
Interventions: Volanesorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encinitas, California • San Francisco, California • Boca Raton, Florida + 25 more

Conditions: Hyperlipidemia
Interventions: Omega-3 fatty acid (Eicosapentaenoic acid); Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Alzheimer's Disease, Dementia
Interventions: Aripiprazole, Olanzapine, Risperidone; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions: RN0361; Drug
Lead sponsor: Ikaria Bioscience Pty Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more

Conditions: Hypercholesterolemia, Heterozygous Familial
Interventions: mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 20
States / cities: Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more

Conditions: Sedentary Behavior, Hypertriglyceridemia
Interventions: Interrupting Prolonged Sitting with Periodic Interval Exercise: Effect on Postprandial Lipemia; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hyperlipidemias, Hyperglycemia
Interventions: Golden Black Seed; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Lipodystrophy
Interventions: Metreleptin; Biological
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 14 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence in Adolescents

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

The Northwest Coalition for Primary Care Practice Support

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Pediatric Reporting of Adult-Onset Genomic Results

Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers

Effect of Cinnamon on Glucose and Lipid Levels in Non-Insulin Dependent Type 2 Diabetes Mellitus

Antihyperlipidemic Effects of Oyster Mushrooms

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

The Effect of Providing Free Samples of Generic Cardiovascular Medications to Physicians

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Standard Process 21 Day Purification Program Project

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

Side Effects of Newer Antipsychotics in Older Adults

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Interrupting Prolonged Sitting With Periodic Interval Exercise: Effect on Postprandial Lipemia

Golden Black Seed: Support of Metabolic Health and General Wellness.

Short-term Effects of Leptin in People With Lipodystrophy